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ABSTRACT 
The present investigation was focus to prepared and characterized eudragit coated pectin microspheres for the delivery of mesalamine and 
prednisolone to the colon. The pectin microspheres were prepared using emulsion dehydration technique. A 33 full factorial design (three 
variables in three levels) was employed to evaluate the combined effect of the selected independent variables: drugs to polymer ratio, 
emulsifier concentrations and stirring speed on dependent variables such as particle size and size distribution, percentage yield, % drug 
entrapment and swelling ratio. Optimized formulation i.e. F18, F24, and F27 were coated with eudragit S100 by the solvent evaporation 
technique to prevent drug release in the stomach. Eudragit S100 coated pectin microspheres were further characterized for coating thickness 
and in-vitro release kinetics. The cumulative percent drug release of mesalamine and prednisolone from formulation in pH 7.4 phosphate buffer 
was found to be 97.01 + 1.35% and 96.89 + 0.67% for mesalamine and prednisolone, respectively. Optimized formulation (F24) was 
characterized for in-vivo studies. The eudragit-coated pectin microspheres may improve therapeutic efficacy by local action and reduce the side 
effects by minimizing the systemic absorption of mesalamine and prednisolone. Amalgamation of mesalamine and prednisolone in therapeutic 
regimen will show synergism action for treatment of Ulcerative Colitis (UC). 
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INTRODUCTION 
Amongst the various routes of drug delivery, oral route is the 
most preferred route for patient and the clinician alike1 
although oral delivery has become a widely accepted route of 
administration of therapeutic drugs; the gastrointestinal 
tract presents several formidable barriers to drug delivery2. 
The site-specific delivery of drugs to lower parts of the GI 
tract is advantageous for localized treatment of several 
colonic diseases, mainly inflammatory bowel disease (IBD) 
like ulcerative colitis (UC) and crohn’s disease (CD), irritable 
bowel syndrome, and colon cancer. Precise colon drug 
delivery requires that the triggering mechanism in the 
delivery system only respond to the physiological conditions 
particular to the colon. Incessant efforts have been made on 
manipulative colon targeted drug delivery systems with 
improved site specificity and versatile drug release kinetics 
to fulfil different therapeutic needs3. 
Ulcerative colitis (UC) is a chronic disorder that affects the 
mucosal lining of the large intestine (colon) and rectum. It is 
an intermittent disease, with periods of exacerbated 
symptoms, and periods that are relatively symptom-free. It is 
treated as an autoimmune disease. Treatment and 
management includes successful suppression of active 
inflammatory disease medically and attempt to conserve the 
small bowel. Therapeutic regimens are based upon the 
severity of UC and the extent of gastrointestinal tract 
involvement4. 
Mesalamine (MSM) also known as mesalazine or 5-
aminosalicylic acid, is an anti-inflammatory drug used to 
treat inflammatory bowel disease, such as UC and mild-to-
moderate CD. Therapeutic agents containing mesalamine are 
first-line therapy for patients with UC. Mesalamine 
diminishes inflammation by blocking cyclooxygenase and 
inhibiting prostaglandin production in the colon5. 
Prednisolone (PRD) is a synthetic glucocorticoid used as 
anti-inflammatory or immunosuppressive agent. It reduces 
inflammatory reaction by limiting the capillary dilatation and 
permeability of the vascular structures. It is the second line 
drug in the therapy of UC. Prednisolone can inhibit leukocyte 
infiltration at the site of inflammation, interfere with 
mediators of inflammatory response, and suppress humoral 
immune responses6. The combination may result in 
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synergistic action for the treatment of the UC and may cause 
significant lowering of treatment failure rate along with 
slower development of resistance. 
Most of the colon-specific drug delivery systems developed 
so far is single-unit systems. On the contrary, multi-
particulate systems can offer several advantages compared 
to single dosage forms, for example more reliable drug 
release profiles and less local irritation. In particular, 
multiple-unit systems based on such specifically 
biodegradable polymers showed to quickly spread out on 
their arrival to the colon, with a sharp increase of surface 
area exposed to bacterial breakdown that produces a rapid 
drug release and thereby improves drug absorption7, 8. 
Pectin is a predominately linear polymer of mainly α-(1-4)-
linked D-galacturonic acid residues interrupted by 1, 2-
linked L-rhamnase residues. Pectin is suitable for use as 
colon-specific drug delivery vehicle as it is selectively 
digested by colonic microflora to release drug with minimal 
degradation in upper gastrointestinal tract. Biodegradable 
pectin microspheres offer a novel approach for developing 
sustained release drug delivery systems that have potential 
for colonic drug delivery 9,10. 
Eudragit S100 is an anionic copolymer based on methacrylic 
acid and methyl methacrylate. It is a polyacrylic resin that 
has been suggested to be used in microencapsulation for 
controlled-release applications due to its unique solubility 
profile. The free carboxylic acid groups make the polymer pH 
sensitive, being soluble at 7 or above pH 7 so suitable for 
targeting of drug into the colon11. 
Thus, in the present work, pectin and Eudragit S100 (pH-
responsive enteric polymer) were chosen to fabricate 
microperticulate drug delivery systems for site-specific 
delivery of mesalamine and prednisolone for the effective 
treatment of Ulcerative colitis (UC). The proposed delivery 
system eudragit-coated pectin microspheres is premised to 
protect the drug loss in the upper GI tract because of the 
deterrent nature of Eudragit S100 (ES) to the milieu of the 
upper GI tract and to deliver drugs upon reaching the colon 
due to the amiable pH of the colonic fluid. Moreover the 
proposed microparticulate system will improve therapeutic 
efficacy by local action. 
MATERIALS AND METHODS 
Mesalamine (MSM) and Prednisolone (PRD) were supplied 
as a gift samples by Cipla Ltd., Ratlam (India) and Kwality 
Pharmaceuticals Pvt. Ltd., Amritsar (India) respectively. 
Pectin was purchased from Himedia Laboratories Limited, 
Mumbai. Eudragit S100 was obtained as a gift sample from 
Ranbaxy Laboratory Limited, India. All other chemicals and 
reagents used were of analytical grades. 
Preparation of microspheres 
The pectin microspheres were prepared by emulsion 
dehydration technique as reported by Esposito et al.12. Pectin 
and drugs were dissolved in 20 ml of distilled water and 
stirred overnight to solubilize completely. Drug-Polymer 
ratio (w/v) was used as 1:1, 1:2 and 1:3. The ratio of both the 
drug taken in equal amount and this drugs-polymer solution 
was dispersed in 50 ml iso-octane containing Span 85 and 
stirred continuously to obtain stable water/oil (w/o) 
emulsion. The solution was rapidly cooled to 15ºC and then 
50 ml of acetone was added in order to dehydrate the pectin 
droplets. This system was maintained under mechanical 
agitation at 25ºC for 30 min. to allow the complete solvent 
evaporation. The microspheres were washed with acetone, 
collected and freeze dried overnight and kept in airtight 
container for further studies. 
 
Table 1: Design of Experiment and Optimization of Variables 
Formulation 
Code 
Drugs Polymer Ratio 
(w/v) 
Emulsifier Concentration 
(v/v) 
Stirring Speed 
(rpm) 
F1 1:1 0.5 500 
F2 1:2 0.5 500 
F3 1:3 0.5 500 
F4 1:1 0.5 1000 
F5 1:2 0.5 1000 
F6 1:3 0.5 1000 
F7 1:1 0.5 1500 
F8 1:2 0.5 1500 
F9 1:3 0.5 1500 
F10 1:1 1.0 500 
F11 1:2 1.0 500 
F12 1:3 1.0 500 
F13 1;1 1.0 1000 
F14 1:2 1.0 1000 
F15 1:3 1.0 1000 
F16 1:1 1.0 1500 
F17 1:2 1.0 1500 
F18 1:3 1.0 1500 
F19 1:1 1.5 500 
F20 1:2 1.5 500 
F21 1:3 1.5 500 
F22 1:1 1.5 1000 
F23 1:2 1.5 1000 
F24 1:3 1.5 1000 
F25 1:1 1.5 1500 
F26 1:2 1.5 1500 
F27 1:3 1.5 1500 
 
Jain et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):12-22 
ISSN: 2250-1177                                                                                  [14]                                                                                 CODEN (USA): JDDTAO 
A 33 full factorial design (three variables in three levels) was 
employed to evaluate the combined effect of the selected 
independent variables: drug to polymer ratio (A), emulsifier 
concentrations (B) and stirring speed (C) on dependent 
variables such as particle size and size distribution, 
percentage yield, % drug entrapment and swelling ratio. 
The drug: polymer ratio (1:1, 1:2, 1:3) emulsifier 
concentrations (0.5, 1, 1.5 ml) and stirring speed (500, 1000, 
1500) were varied in batches F1 – F27 as shown in table 1. 
Characterization of microspheres 
Size and size determination 
It was carried out by using compound microscope. Dried 
pectin microspheres were firstly redispersed in distilled 
water. These were then placed on a glass slide. The number 
of divisions of the calibrated eyepiece was counted by a 
micrometer using the stage micrometer13. All formulations 
were characterized for their average particle size, results 
were shown in Fig.2. 
Percentage yield 
Total percentage yield of pectin microspheres calculated by 
weighing of prepared microspheres was divided by total 
amount of the non-volatile components used for the 
preparation of the microspheres14.  
                       
               
                 
      
Results were shown in Fig.2. 
% Drug entrapment  
The microspheres obtained after two washings were 
digested in 10 ml of pectinase solution (4% w/w) for 1 hrs. 
The digested homogenate was analyzed for drugs content at 
332nm for MSM and 246nm for PRD by UV/Visible 
Spectrophotometer (UV- 1800Shimadzu, Japan) 15.  
                  
                       
               
      
Results were shown in Fig.3. 
Swelling ratio 
100 mg of drugs-loaded pectin microspheres and eudragit-
coated pectin microspheres were placed in enzyme-free 
simulated intestinal fluid (SIF, pH 7.4) and allowed to swell 
up to constant weight at 37ºC ± 0.5ºC. The microspheres 
were periodically removed and blotted with filter paper, and 
then their change in weight was measured until attainment 
of equilibrium16. 
SR = ωg−ωo/ωo 
Where, SR indicates swelling ratio; ωo, initial weight of 
microspheres; and ωg, final weight of microspheres, results 
were shown in Table.2. 
Coating of prepared pectin microspheres by eudragit 
S100 
The coating of Eudragit S100 on pectin microspheres was 
done by oil-in-oil solvent evaporation method as reported by 
Lorenzo-Lomora et al17. 
50 mg of pectin microspheres were dispersed in 12% w/v 
acetone in which eudragit S100 was previously dissolved to 
give 1:10 core: coat ratio. This organic phase was then 
poured in light liquid paraffin containing 1% w/v Span 85. 
The system was maintained under agitation speed of 1000 
rpm at room temperature for 3 hours to allow the 
evaporation of solvent. Finally, the coated microspheres 
were filtered, washed with n-Hexane and dried for 24 hrs. All 
prepared pectin microspheres were coated with eudragit 
S100 and weighed and the mean coating weight calculated 
by difference with respect to the initial microspheres 
weight.18 
Coating thickness 
The mean diameter of representative microspheres samples 
of each batch was estimated with a calibrated ocular 
eyepiece. The mean coating thickness was determined by 
difference between the mean diameter of microspheres after 
and before the coating19, results were shown in Table.3. 
In-Vitro drug release studies in simulated 
gastrointestinal fluids of different pH 
On the basis of particle size, percentage yield and 
entrapment efficiency three formulations (F18, F24, and 
F27) of eudragit coated pectin microspheres were evaluated 
for the in-vitro drug release study. The drug dissolution tests 
of microspheres were carried out by the paddle method 
specified in USP XXIII. 100 mg of microspheres were weighed 
accurately and gently spread over the surface of 900 ml of 
dissolution medium as specified in the IP 1996. The content 
were rotated at 100 rpm and thermostatically controlled at 
37±0.5˚C. Sink condition was maintained during dissolution. 
In-Vitro Drug release was studied in simulated 
gastrointestinal fluids of different pH in the following 
sequence, in order to mimic mouth-to-colon transit: In 
simulated gastric fluid (pH 1.2) 2nd hrs; In simulated 
intestinal fluid (pH 6.8) 3rd-4th hrs; In simulated colonic fluid 
(pH 7.4) 5th-24th hrs. 
The medium was filtered through whatmann filter paper 
after 2nd and 5th hrs and the residue on filter paper was 
added to the next medium immediately. The dissolution 
study was continued further and samples were withdrawn at 
suitable time intervals from the dissolution vessel and 
analyzed for drugs content at 332nm for MSM and 246nm for 
PRD by UV/Visible Spectrophotometer (UV- 1800Shimadzu, 
Japan). 20 The % cumulative drug release profile of 
formulations F18, F24 and F27 are shown in Fig.4, 5 and 6. 
Shape and surface morphology 
In order to examine the surface morphology, the pectin 
microspheres and optimized formulations F24 was analysed 
through scanning electron microscope (LEO 435 VP, 
Eindhoven Netherlands). The sample for SEM was prepared 
by lightly sprinkling the microspheres powder on a double 
adhesive tape, which was stuck on an aluminum stub. The 
stubs were then coated with gold to thickness of about 300 Å 
using a sputter coater21. The photomicrographs were taken 
with the help of SEM analyzer, the micrograph depicted in 
Fig.7. 
In- Vivo Studies 22, 23: 
In colitis induced rats 
The protocol of present study was duly approved by the 
Institutional Animal Ethics Committee of Smriti College of 
pharmaceutical sciences, Indore (M.P.) (Reference no. 
12/DB/177 (1) and the studies were carried out in 
accordance with the Council for Purpose & Supervision of 
Experiment on Animals (CPCSEA), Ministry of Social Justice 
& Empowerment Govt. of India. Healthy male wistar rats 
(average weight 230 g) were fasted for 48 hrs before the 
induction of UC. Inflammatory lesions were induced by acetic 
acid. Each group of treated animals contained six rats. The 
colitis group was treated by the following procedure to 
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effectuate an inflammation: After light narcotizing with 
ether, the rats were catheterized 8 cm intrarectally, by the 
4% acetic acid (2 ml/day) for 3 days for full induction of UC 
model. 
Estimation of induction of ulcer colitis (UC) 
Weight loss measurement 
Animals were weighed on the weighing balance before and 
after administration of acetic acid and weight loss after acetic 
acid administration a parameter which indicates induction of 
UC. Body weight of each animal was taken for 14 days and 
result were shown in Fig.8. 
Stool consistency  
Stool consistency, 0 point was given for well formed pellets, 
2 points for pasty and semi formed stools that did not stick to 
the anus, and 4 points was given for liquid stools that stick to 
the anus, result were shown in Table.4. 
Rectal bleeding  
Bleeding was scored as 0 point for no blood, 2 points for 
positive finding, and 4 points for gross bleeding. The mean of 
these scores was forming the clinical score ranging from 0 
(healthy) to 4 (maximal activity of colitis), result were shown 
in Table.5. 
Blood testing  
Blood samples were collected and analyzed for blood glucose 
level, total white blood cell count, neutrophills count and 
monocytes count, result were shown in Fig.9-12. 
Histopathology of colon  
The animals were sacrificed 24 hrs after the last 
drug/particle administration and their colons were resected. 
Resected colon was stored in 10% formalin solution and 
samples were sending for histopathogical studies, the 
micrographs depicted in Fig.13. 
Animals were divided into four groups where each group 
contained 6 animals.  
Group A: Normal control group received normal saline 
Group B: Colitis control group received normal saline 
Group C: Colitis group received microspheres suspension 
Group D: Colitis group received drugs solution 
Colitis group was treated with MSM and PRD solution (dose: 
100 mg/kg and 40 mg/kg) and microspheres suspension 
once a daily dose for 7 days. Dose of microspheres were 
calculated after the determination of entrapment efficiency. 
Colitis control group was treated same as the colitis group 
was treated with normal saline. Normal control group 
contains healthy animals. 
In-Vivo targetability24 
The eudragit coated pectin microspheres were prepared 
using the same amounts of composition except that the 
amount of drugs was replaced with fluorescent dye. 
Fluorescent imaging 
The Fluorescent imaging study was carried out using male 
wistar rats. In experiment, the animal was allowed to fast 
overnight with free access to water. The microspheres were 
administered and after 24 hrs. Animal was sacrificed and 
then colon part send for histopathological study, the 
micrograph depicted in Fig.14. 
Statistical analyses 
The Student t test was used to find the statistical significance. 
Quantitative data were expressed as the mean ± standard 
deviation. P values\0.05 were considered significant. 
 
 
 
Figure 1: Particle size of all formulations of pectin microspheres 
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Figure 2: Percentage yield of optimized formulations of pectin microspheres 
 
 
Figure 3: % Drugs entrapment of optimized formulations of pectin microspheres 
 
Table 2: Swelling ratio of optimized formulations of pectin microspheres 
 
S. No Formulation Code Swelling Ratio 
1 F6 1.18 
2 F16 0.94 
3 F18 1.45 
4 F22 0.96 
5 F23 1.10 
6 F24 1.44 
7 F25 1.05 
8 F26 1.13 
9 F27 1.60 
All the values are expressed as + S.D, n=3 
 
Table 3: Coating thickness of optimized formulations of pectin microspheres 
S. N. Selected formulation Coating thickness (µm) 
1 F18 111.06 
2 F24 154.63 
3 F27 118.52 
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Figure 4: Percent cumulative release of mesalamine from optimized formulations of eudragit S100 coated pectin 
microspheres in PBS (pH 7.4) 
 
 
Figure 5: Percent cumulative release of prednisolone from optimized formulations of eudragit S100 coated pectin 
microspheres in PBS (pH 7.4) 
 
Figure 6: Percent cumulative drug release from optimized formulation of eudragit S100 coated pectin microspheres 
(F24) in PBS (pH 7.4)   
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(a)                                                                                        (b) 
Figure 7: SEM photographs optimized formulations (F24) (a) Pectin microspheres (b) Eudragit S100 coated pectin 
microspheres 
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Figure 8: Body weight comparison of different groups of animals 
 
Table 4: Stool consistency of different groups of animals 
S. N. Day Normal Control group Colitis Control group Microspheric group Drugs Solution group 
1 1 Pellets Pellets Pellets Pellets 
2 7 Pellets Pasty Pasty Pasty 
3 14 Pellets Liquid Pellets Pasty 
 
Rectal Bleeding: 
Table 5: Rectal Bleeding of Different Groups of Animals 
S. No Day Normal Control group Colitis Control 
group 
Microspheric 
group 
Drugs Solution 
group 
1 1 No Bleeding No Bleeding No Bleeding No Bleeding 
2 7 No Bleeding Positive Positive Positive 
3 14 No Bleeding Gross No Bleeding No Bleeding 
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Blood Testing:  
 
NC- Normal control group         CC-Colitis control group        MS- Microspheric group        SO- Drugs solution group 
Figure 9: Blood glucose level comparison of different groups of animals 
 
NC- Normal control group        CC-Colitis control group         MS- Microspheric group         SO- Drugs solution group 
Figure 10:  Total WBC count comparison of different groups of animal 
 
NC- Normal control group         CC-Colitis control group       MS- Microspheric group         SO- Drugs solution group 
Figure 11: Neutrophils count comparison of different groups of animals 
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NC- Normal control group           CC-Colitis control group          MS- Microspheric group         SO- Drugs solution group 
Figure12: Monocytes count comparison of different groups of animals 
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(a)- Normal control group          (b)-Colitis control group          (c)- Microspheric group          (d) - Drugs solution group 
Figure 13: Histological microscopic photographs of different groups of animals 
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Figure 14: Fluorescent microscopic photograph of optimized formulation (F24) in colitis induced rat 
RESULT AND DISCUSSION 
Pectin microspheres containing mesalamine and 
prednisolone were prepared by emulsion-dehydration 
technique. A 33 full factorial design (three variables in three 
levels) was employed to evaluate the combined effect of the 
selected independent variables: drug to polymer ratio (A), 
emulsifier concentrations (B) and stirring speed (C) on 
dependent variables such as particle size and size 
distribution, percentage yield, % drug entrapment and 
swelling ratio. The drug: polymer ratio (1:1, 1:2, 1:3) 
emulsifier concentrations (0.5, 1, 1.5) and stirring speed 
(500, 1000, 1500) were varied in batches F1 – F27 as shown 
in table 1. 
Twenty seven formulations were prepared which were 
characterized for their average particle size and on the basis 
of particle size selected batches optimized for percentage 
yield, % drug entrapment and swelling ratio, results depicted 
in Fig.1, 2 and 3 and Table 2 respectively.  
Particle size of the pectin microspheres increased from 
359.66 to 1300.40 μm with decreasing in stirring speed from 
1500 to 500 rpm. The average particle size of microspheres 
increased with decreasing amount of emulsifier (span 85), 
which got dispersed into larger droplets. The particle size of 
pectin microspheres decreased with increasing amount of 
span 85 from 0.5 to 1.50%. Increased emulsifier 
concentration led to the formation of particles with a lower 
mean geometric diameter. Increasing concentration of span 
85 from 0.5 to 1.50 % v/v led to stabilization of the emulsion 
droplets avoiding their coalescence, resulting in smaller 
microspheres. The particle size of pectin microspheres 
decreased with increasing stirring rate from 500 to 1500 
rpm. Results showed that the particle size of microspheres 
was controlled by stirring rate. These results show that a 
high stirring speed produced smaller microspheres due to 
the smaller emulsion droplets produced by a higher stirring 
speed, which provided more energy to disperse the oil phase 
in water, but higher agitation speeds resulted in irregularly 
shaped microspheres. The particle size of pectin 
microspheres decreased from 359.66 to 1300.40 μm with 
increasing the amount of drugs. The drug entrapment 
efficiency varied from 61.14 + 0.5% to 75.59 + 0.96% for 
mesalamine and 70.16 + 1.27% to 81.53 + 0.73% for 
prednisolone. The highest entrapment efficiency and 
percentage yield were found with F18, F24, and F27 
formulations, therefore these formulations were selected for 
further evaluation. 
On the basis of particle size, Percentage yield, % drugs 
entrapment and swelling ratio optimized formulation i.e. 
F18, F24, and F27 were coated with eudragit S 100, therse 
frmulations were further characterized for coating thickness, 
and results were shown in table 4. 
The in vitro drug release study of optimized formulation 
(F24) was carried out by buffer change method to mimic the 
GIT environment. The cumulative percentage drug release 
from Eudragit-coated pectin microspheres showed the 
desired rate, as there was no measurable drug release 
observed up to 2 hours in SGF (pH 1.2), and release as 
intended in the simulated distal ileum and colon. Cumulative 
percent drug release of mesalamine and prednisolone from 
formulation in pH 7.4 phosphate buffer was found to be 
97.01 + 1.35% and 96.89 + 0.67% for mesalamine and 
prednisolone, respectively as shown in Fig. 4, 5 and 6. 
Optimized Formulation (F24) and eudragit S100 coated 
pectin microspheres were spherical, non-aggregated with 
smooth surface, in scanning electron micrographs as shown 
in Fig. 7. 
In-vivo study of optimized formulation (F24) was performed 
in colitis induced rats and compared with drugs solution to 
treat UC in male wistar rats. Study shows that optimized 
formulation effectively treat UC in rats. Male wistar rats 
(average weight 230 g) were fasted for 48 hrs before the 
induction of ulcerative colitis. Inflammatory lesions were 
induced by acetic acid. Each group of treated animals 
contained at least six rats. The colitis group was treated by 
the following procedure to effectuate an inflammation: After 
light narcotizing with ether, the rats were catheterized 8 cm 
intrarectally, by the 4% acetic acid (2 ml/day) for 3 days for 
full induction of UC model46. 
Animals were weighed on the weighing balance before and 
after administration of acetic acid and weight loss after acetic 
acid administration a parameter which indicates induction of 
UC47. Stool consistency, 0 point was given for well formed 
pellets, 2 points for pasty and semi formed stools that did not 
stick to the anus, and 4 points was given for liquid stools that 
stick to the anus47. Bleeding was scored as 0 point for no 
blood, 2 points for positive finding, and 4 points for gross 
bleeding. Results of body weight comparison of different 
groups of animals, stool consistency and rectal bleeding of 
Jain et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):12-22 
ISSN: 2250-1177                                                                                  [22]                                                                                 CODEN (USA): JDDTAO 
animals are shown in figure 8, table 4 and 5 respectively.  
The mean of these scores was forming the clinical score 
ranging from 0 (healthy) to 4 (maximal activity of colitis) 
47.Blood samples were collected and analyzed for total white 
blood cell count, neutrophills count, and blood glucose 
level47. The results are shown in figure 9, 10 and 11. 
The animals were sacrificed 24 hrs after the last 
drug/particle administration and their colons were resected. 
Resected colon was stored in formaline solution and samples 
were sending for histopathogical studies48. Histological 
microscopic photographs are shown in figure 13. 
Four groups of animals were prepared each group contains 6 
animals, Male wistar rats (average weight 230 gm) Two 
Colitis group, Colitis control group and Normal control 
group. 
Colitis group was treated with Mesalamine and Prednisolone 
solution (dose: 100 mg/kg and 40 mg/kg) and microspheres 
suspension once a daily dose for 7 days. Dose of 
microspheres were calculated after the determination of 
entrapment efficiency. 
Colitis control group was treated same as the colitis group 
was treated with normal saline. Normal control group 
contains healthy animals. The pectin microspheres were 
prepared using the same amounts of ingredients except that 
the amount of drugs was replaced with fluorescent dye. 
The Fluorescent imaging study was carried out using male 
wistar rats. In experiment, the animal was allowed to fast 
overnight with free access to water. The microspheres were 
administered and after 24 hrs. animal was sacrificed and 
then colon part send for histopathological study.  
Fluorescent microscopic photograph of colitis induced rat 
colon showed the microspheres reaches in the colonic 
mucosa of rat which proves the targeting of microspheres. 
The Fluorescent microscopic photograph of optimized 
formulation (F24) in colitis induced rat shown in figure 14. 
The optimized microspheres (F 24) produced were generally 
spherical having size range 600-700 µm.. The designed site 
specific delivery of Mesalamine and Prednisolone from the 
system may reduced the side effect of drugs by targeting the 
drugs into colon. The experiment results demonstrated that 
eudragit S100 coated pectin microspheres have potential to 
be used in the treatment of ulcerative colitis.  
Conclusion 
Eudragit S100 coated pectin microspheres have the potential 
to be an efficient, viable, safe and cost-effective system for 
administration of mesalamine and prednisolone on account 
of their biodegradability, biocompatibility, and suitability for 
oral applications. 
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